[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-wheezing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-wheezing":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100658839","phase-4-prevent-wheeze-trial-100658839",false,"NCT07858773","Prevent Wheeze Trial","Single Dose Dexamethasone for the Prevention of Recurrent Wheeze in at Risk Children With First Episode LRTI: a Multi-country RCT in Two Low- and Middle-income Countries.","PRE-WHEE","Inclusion criteria:\n\n1. Age 3-24 months\n2. LRTI (WHO definition LRTI: Cough or difficulties breathing\n\n   \\+ plus either fast breathing ( 2-12 months: \\> 50 breaths\u002Fminute 13-24 months: \\>40\u002Fminute) or: lower chest wall indrawing (retractions\u002Fnasal flare\u002Fdifficulties breathing\u002Fwheeze) Acute:\\\u003C7 days duration of LRTI symptoms\n3. No history of previous LRTI\u002Fwheeze\n4. \\+ 1 or more risk factors for recurrent wheeze:\n\n   * Clinical wheeze by presentation (indicated in TAL score\\>=1 for wheeze item). The scoring matrix is here and in the annex.\n   * Indoor pollution exposure: Tobacco smoke exposure a) during pregnancy or b) in house where child lives (regular \\>= 2week) or polluting cooking facility\n   * Atopic\u002Fallergic disease in child\n   * Atopic\u002Fallergic\u002Fasthma in sibling, mother or father\n   * PT week 34-36 or BW 2000-2500g\n   * Eosinophil count \\>0.30 Informed consent\n\nExclusion criteria:\n\n* Chronic illness other than atopy (eczema, food allergy),\n* Systemic corticosteroid treatment the previous 6 months\n* Inhaled corticosteroid treatment, at any time, for \\>2 weeks\n* Clinical suspicion of bacterial pneumonia based upon a temperature ≥39.0°C and at least one of the following: 1. Unilaterally decreased breath sounds or unilateral percussion dullness 2. Pulmonary lobar consolidation and\u002For radiological high suspicion of empyema on chest x-ray if this is obtained prior to inclusion in the trial. Fills other criteria for high likelihood of bacterial pneumonia (on clinicians' evaluation or CRP\\>40)\n* Evidence of any bacterial infection other than bacterial LRTI, including, but not exclusively: 1. Clinical septicemia 2. Urinary tract infection 3. Meningitis\n* participation in another trial\n* varicella infection or contact during the last 2-3 weeks\n* Fulfill criteria for ICS at time of inclusion, at treating physicians discretion, guided by annex on criteria for unblinding due to medical condition needing open CS treatment (criteria for unbinding Criteria for unblinding.docx)\n* Severe wheeze defined by TAL score\\* \\>=11 or need for intensive care unit treatment with invasive ventilation at screening.\n* Previous admission for a LRTI or physician verified LRTI","ALL","3 Months","24 Months",{"count":21,"type":22},486,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This trial investigates whether a single dose of dexamethasone will prevent recurrent wheezing in children at high-risk for asthma admitted to hospital with a lower respiratory tract infection (LRTI). Eligible children will be identified and enrolled upon hospital admission or during hospitalisation and allocated to receive either dexamethasone 0.6 mg\u002Fkilogram body weight or the similar number of placebo tablets (allocation ratio 1:1). The follow-up is 12 months and comprises scheduled on-site examinations by physician and study nurse, scheduled phone contacts, and registrations of new LRTI-episodes (if any). Nasopharyngeal swabs and blood will be collected at specified visits. The children will be invited to a follow-up study at school age for lung function assessments.",[28,29],"Lower Respiratory Tract Infection (LRTI)","Recurrent Wheezing",[31,32,33,34,35,36,37,38,39,40,41],"recurrent wheezing","lower respiratory tract infection","LRTI","asthma","low- and middle-income country","LMIC","Nepal","pediatric","South Africa","dexamethasone","corticosteroids","NOT_YET_RECRUITING","2026-09-30",{"date":45,"type":46},"2026-10-05","ACTUAL",{"date":48,"type":22},"2027-02-01",{"date":50,"type":22},"2029-01-30",{"name":52,"class":53},"Norwegian University of Science and Technology","OTHER",2]